知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.016 秒)

    Virally-inactivated growth factors-containing platelet lysate depleted of PDGF and VEGF and preparation method thereof
    1.
    发明授权
    Virally-inactivated growth factors-containing platelet lysate depleted of PDGF and VEGF and preparation method thereof 有权
    含有PDGF和VEGF的病毒灭活生长因子血小板裂解物及其制备方法

    公开(公告)号：US09034646B2

    公开(公告)日：2015-05-19

    申请号：US13684746

    申请日：2012-11-26

    申请人： Thierry Burnouf ,  Cheng-Yao Su

    发明人： Thierry Burnouf ,  Cheng-Yao Su

    IPC分类号： C12N5/08 ,  A61K35/16 ,  C12N5/00 ,  A61K38/18 ,  A61K38/30

    CPC分类号： C12N5/0018 ,  A61K35/19 ,  A61K38/1808 ,  A61K38/1841 ,  A61K38/30 ,  A61K2300/00

    摘要： The invention concerns human platelet extracts rich in growth factors (PGF) for wound healing and stem cell expansion. Accordingly the subject invention relates to a virally-inactivated growth factors-containing platelet lysate depleted of PDGF and VEGF, which is preferably enriched in TGF, IGF and EGF-rich. The present invention further concerns a method for obtaining a platelet lysate comprising the steps of contacting a starting platelet concentrate with a solvent and/or a detergent, incubating the starting platelet concentrate with the solvent and/or detergent for a period of at least 5 minutes to 6 hours, at a pH maintained in a range from about 6.0 to about 9.0, and at a temperature within the range of from 2° C. to 50° C., optionally removing the solvent and/or the detergent by oil extraction and obtaining an aqueous protein phase, and incubating the solvent and/or detergent-treated platelet concentrate or the aqueous protein phase with charcoal.

    摘要翻译： 本发明涉及富含生长因子（PGF）的人血小板提取物用于伤口愈合和干细胞扩增。 因此，本发明涉及耗尽PDGF和VEGF的病毒灭活的含生长因子的血小板裂解物，其优选富含富含TGF，IGF和富含EGF的血小板裂解物。 本发明还涉及获得血小板裂解物的方法，其包括以下步骤：使起始血小板浓缩物与溶剂和/或洗涤剂接触，将起始血小板浓缩物与溶剂和/或洗涤剂一起孵育至少5分钟 至约6小时，pH保持在约6.0至约9.0，温度范围为2℃至50℃，任选地通过油提取除去溶剂和/或洗涤剂; 获得蛋白质水相，并将溶剂和/或洗涤剂处理的血小板浓缩物或水性蛋白质相与活性炭一起温育。

    CLOTTABLE CONCENTRATE OF PLATELET GROWTH FACTORS AND PREPARATION METHOD THEREOF
    2.
    发明申请
    CLOTTABLE CONCENTRATE OF PLATELET GROWTH FACTORS AND PREPARATION METHOD THEREOF 审中-公开
    平板生长因子的可调浓度及其制备方法

    公开(公告)号：US20110027257A1

    公开(公告)日：2011-02-03

    申请号：US12744200

    申请日：2009-01-07

    申请人： Thierry Burnouf ,  Cheng-Yao Su

    发明人： Thierry Burnouf ,  Cheng-Yao Su

    IPC分类号： A61K38/48 ,  C07K14/49 ,  C07K14/495 ,  C07K14/485 ,  C07K14/65 ,  C07K14/50 ,  A61K38/18 ,  A61K38/30 ,  A61K38/22 ,  A61K38/39 ,  A61K8/64 ,  A61P17/02 ,  A61P19/00 ,  A61P9/00 ,  A61P7/02 ,  A61Q90/00

    CPC分类号： A61K38/30 ,  A61K8/64 ,  A61K38/18 ,  A61K38/1808 ,  A61K38/1825 ,  A61K38/1841 ,  A61K38/1858 ,  A61K38/1866 ,  A61K38/39 ,  A61K2800/10 ,  A61Q19/00 ,  C07K14/49 ,  A61K2300/00

    摘要： The present disclosure relates to a clottable concentrate of platelet growth factors for therapeutic and/or cosmetic use, preferably comprising the growth factors PDGF, TGT-β, IGF, EGF, CTGF, bFGF and VEGF. In a preferred embodiment, the clottable concentrate of platelet growth factors does not induce blood cell-related transfusion reactions. The present disclosure also relates to a method for preparing a clottable concentrate of platelet growth factors including the steps of contacting a platelet concentrate with a solvent and/or a detergent, incubating the platelet concentrate with the solvent and/or detergent for a period of at least 5 minutes to 6 hours, at a pH maintained in a range from about 6.0 to about 9.0, and at a temperature within the range of from 2° C. to 50° C., preferably within the range of from 25° C. to 45° C., and removing the solvent and/or the detergent by oil extraction and/or chromatographic means.

    摘要翻译： 本公开内容涉及用于治疗和/或美容使用的可凝结的血小板生长因子浓缩物，优选包含生长因子PDGF，TGT-和bgr; IGF，EGF，CTGF，bFGF和VEGF。 在优选的实施方案中，血小板生长因子的可凝结浓缩物不诱导与血细胞相关的输血反应。 本公开还涉及一种制备血小板生长因子的可凝结浓缩物的方法，包括以下步骤：使血小板浓缩物与溶剂和/或洗涤剂接触，将血小板浓缩物与溶剂和/或洗涤剂一起温育一段时间 至少5分钟至6小时，pH值范围为约6.0至约9.0，温度范围为2℃至50℃，优选为25℃。 至45℃，并通过油提取和/或色谱法除去溶剂和/或洗涤剂。

    Set of Disposable Bags for Viral Inactivation of Biological Fluids
    3.
    发明申请
    Set of Disposable Bags for Viral Inactivation of Biological Fluids 审中-公开
    一套用于生物流体病毒灭活的袋子

    公开(公告)号：US20070219524A1

    公开(公告)日：2007-09-20

    申请号：US11579163

    申请日：2006-02-01

    申请人： Thierry Burnouf ,  Magdy El-Ekiaby ,  Hadi Alphonse ,  Miryana Radosevich

    发明人： Thierry Burnouf ,  Magdy El-Ekiaby ,  Hadi Alphonse ,  Miryana Radosevich

    IPC分类号： A61B19/00

    CPC分类号： A61J1/10 ,  A61J1/12 ,  A61L2/0088

    摘要： The invention relates to a set system of disposable bags comprising at least one viral inactivation bag (1), comprising an inner compartment (4), an inlet facility (5) and an outlet facility (6), which are both connected to the inner compartment (4), the bag (1) being characterised in that the inner compartment (4) has an ovoid longitudinal section, and at least one funnel bag (9), and/or a column chromatography bag (15), the different bags being connectable with each other, and to the use of said set system of disposable bags for the viral inactivation of biological fluids with excellent protein recovery.

    摘要翻译： 本发明涉及一种包括至少一个病毒灭活袋（1）的一次性袋的集合系统，其包括内部隔间（4），入口设备（5）和出口设施（6），它们都连接到内部 所述袋（1）的特征在于，所述内隔室（4）具有卵形纵向截面，以及至少一个漏斗袋（9）和/或柱色谱袋（15），所述不同袋 可以彼此连接，以及使用所述一次性袋装置系统，用于病毒灭活具有优异蛋白质回收的生物流体。

    Plasma preparation or serum preparation and process for producing the same
    5.
    发明申请
    Plasma preparation or serum preparation and process for producing the same 有权
    血浆制剂或血清制备及其制备方法

    公开(公告)号：US20060127874A1

    公开(公告)日：2006-06-15

    申请号：US10531570

    申请日：2003-10-16

    申请人： Sakae Sato ,  Tetsuo Sato ,  Thierry Burnouf ,  Miryana Radosevich ,  Hadi Goubran

    发明人： Sakae Sato ,  Tetsuo Sato ,  Thierry Burnouf ,  Miryana Radosevich ,  Hadi Goubran

    IPC分类号： A01N1/02 ,  C12N5/08

    CPC分类号： A61L2/0017 ,  A61K35/16 ,  A61M1/0272 ,  A61M1/3633 ,  A61M2202/0415

    摘要： The present invention relates to a plasma product or a serum product with an extremely low risk of viral contamination and a method for producing the same. Before treating plasma or serum to be used as a raw material for producing a plasma product or a serum product using a virus removal membrane, leucocytes contaminating the blood are removed. Thus, a plasma product or a serum product with an extremely low risk of viral contamination can be efficiently produced while preventing clogging. Since clogging scarcely arises, it is possible to carry out efficient filtration without applying an elevated pressure as the filtration proceeds.

    摘要翻译： 本发明涉及具有极低的病毒污染风险的血浆产品或血清产品及其制备方法。 在将血浆或血清用作生产血浆产物或使用病毒去除膜的血清产物的原料之前，除去污染血液的白细胞。 因此，可以有效地生产具有极低病毒污染风险的血浆产品或血清产品，同时防止堵塞。 由于几乎不产生堵塞，因此随着过滤的进行，可以不施加高压而进行有效的过滤。

    Preparation of a high-purity human factor IX concentrate and other plasmatic proteins and their therapeutic use
    6.
    发明授权
    Preparation of a high-purity human factor IX concentrate and other plasmatic proteins and their therapeutic use 失效
    制备高纯度人因子IX浓缩液及其他血浆蛋白及其治疗用途

    公开(公告)号：US5457181A

    公开(公告)日：1995-10-10

    申请号：US683109

    申请日：1991-04-11

    申请人： Catherine Michalski ,  Thierry Burnouf

    发明人： Catherine Michalski ,  Thierry Burnouf

    IPC分类号： G01N33/48 ,  A61K35/14 ,  A61K38/00 ,  A61K38/43 ,  B01D15/08 ,  C07K1/16 ,  C07K1/18 ,  C07K1/22 ,  C07K1/30 ,  C07K14/00 ,  C07K14/745 ,  C12N9/64 ,  G01N30/88

    CPC分类号： C12N9/647 ,  C07K14/745 ,  A61K38/00

    摘要： The present invention relates to a method for preparing a high purity Factor IX concentrate. The starting material for the process is the supernatant fraction of a cryoprecipitated human plasma. A pre-purification step is performed by DEAE-Sephadex chromatography. The resulting Factor IX fraction has a specific activity of at least 0.5 IU/mg protein. The purification method of the invention comprises two successive chromatography separations. First, ion-exchange chromatography on DEAE-sepharose is conducted so that the Factor IX is eluted when the ionic force of the buffer is increased to 0.34-0.38M sodium chloride. Then, affinity chromatography is conducted on heparin-sepharose. The elution buffer is a citrate buffer at a pH of 7.4 adjusted with 0.45M sodium chloride and supplemented with arginine as a stabilizer for Factor IX activity. Lysine is added as a stabilizer before freeze-drying of the purified Factor IX.

    摘要翻译： 本发明涉及制备高纯度因子IX浓缩物的方法。 该方法的起始原料是冷沉淀的人血浆的上清液部分。 通过DEAE-Sephadex色谱法进行预纯化步骤。 所得的因子IX级分具有至少0.5IU / mg蛋白质的比活性。 本发明的纯化方法包括两次连续的色谱分离。 首先，进行DEAE-琼脂糖凝胶上的离子交换层析，使得当缓冲液的离子力增加至0.34-0.38M氯化钠时，因子IX被洗脱。 然后，对肝素琼脂糖进行亲和层析。 洗脱缓冲液是用0.45M氯化钠调节pH 7.4的柠檬酸盐缓冲液，补充精氨酸作为因子IX活性的稳定剂。 加入赖氨酸作为稳定剂，然后冷冻干燥纯化的因子IX。

    Process for preparing a concentrate of blood coagulation factor VIII-von willebrand factor complex from total plasma
    9.
    发明授权
    Process for preparing a concentrate of blood coagulation factor VIII-von willebrand factor complex from total plasma 失效
    从总血浆中制备凝血因子VIII-von willebrand因子复合物的浓缩物的方法

    公开(公告)号：US5679776A

    公开(公告)日：1997-10-21

    申请号：US577368

    申请日：1990-09-05

    申请人： Miryana Burnouf-Radosevich ,  Thierry Burnouf

    发明人： Miryana Burnouf-Radosevich ,  Thierry Burnouf

    IPC分类号： A61K35/16 ,  A61K38/37 ,  C07K14/755 ,  G01N33/86 ,  A61K38/36 ,  C07K1/30 ,  C07K1/36

    CPC分类号： C07K14/755

    摘要： The invention relates to a process for preparing a concentrate of Factor VIII-von Willebrand factor complex having high specific activity from total (non-cryoprecipitated) plasma. The process comprises pre-purifying by means of a double treatment with barium chloride and with aluminium hydroxide. The process then comprises purification by chromatography on an anion exchange resin, of the DEAE-Fractogel type. The process includes a step of viral inactivation by means of a treatment with solvent-detergent. The process also makes it possible to recover fibrinogen, albumin, immunoglobulins, antithrombin III, fibronectin and prothrombin complex, from the same plasma. The different concentrates obtained using the process according to the invention are intended, in particular, for therapeutic use.

    摘要翻译： 本发明涉及一种从总（非冷沉淀）等离子体制备具有高比活性的因子VIII-von Willebrand因子复合物浓缩物的方法。 该方法包括通过用氯化钡和氢氧化铝进行双重处理的预纯化。 该方法然后包括通过色谱法在DEAE-Fractogel型阴离子交换树脂上进行纯化。 该方法包括通过用溶剂 - 洗涤剂处理的病毒灭活步骤。 该方法还可以从相同的血浆中回收纤维蛋白原，白蛋白，免疫球蛋白，抗凝血酶III，纤连蛋白和凝血酶原复合物。 使用根据本发明的方法获得的不同浓缩物特别用于治疗用途。

    Concentrate of thrombin coagulable proteins, the method of obtaining same and therapeutical use thereof
    10.
    发明授权
    Concentrate of thrombin coagulable proteins, the method of obtaining same and therapeutical use thereof 失效
    凝血酶凝血蛋白的浓缩物，获得其凝血因子的方法和治疗用途

    公开(公告)号：US5260420A

    公开(公告)日：1993-11-09

    申请号：US873106

    申请日：1992-04-24

    申请人： Miryana Burnouf-Radosevich ,  Thierry Burnouf

    发明人： Miryana Burnouf-Radosevich ,  Thierry Burnouf

    IPC分类号： A61K38/36 ,  A61L24/10 ,  A61K35/16 ,  A61K9/14

    CPC分类号： A61L24/106 ,  A61K38/363

    摘要： The invention provides a thrombin coagulable protein concentrate,, the preparation thereof and the therapeutic use thereof. This concentrate has a fibrinogen content greater than 70% and a sufficient amount of endogenous Factor XIII. It may be solubilized at ambient temperature. Its preparation comprises at least one cold precipitation step with dilute ethanol and uses total plasma as a starting product. The concentrate of the invention makes it possible more particularly to obtain an injectable fibrinogen and a biological glue of high quality.

    摘要翻译： 本发明提供凝血酶凝固蛋白浓缩物，其制备及其治疗用途。 该浓缩物具有大于70％的纤维蛋白原含量和足够量的内源性因子XIII。 它可以在环境温度下溶解。 其制备方法包括至少一个冷稀释步骤与稀乙醇，并使用总等离子体作为起始产物。 本发明的浓缩物可以更具体地获得高质量的可注射纤维蛋白原和生物胶。